ArticleRadiation oncology (London, England)2018
High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events.
Article in Radiation oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Intensity-Modulated Brachytherapy (IMBT): Static and Dynamic Techniques.International journal of radiation oncology, biology, physics · 2019Pooled it
- Trial
- Development of a patient-specific adaptive ring for organ at risk contours in high-dose-rate brachytherapy gynecologic cancers.Journal of contemporary brachytherapy · 2026Article
- A Retrospective Analysis Comparing the Dosimetric Parameters of Two Rectum-Sparing Techniques During Intracavitary Brachytherapy with Tandem-Ring Applicators for Cervical Cancer.Cancer management and research · 2025Article
- A deep learning-based 3D Prompt-nnUnet model for automatic segmentation in brachytherapy of postoperative endometrial carcinoma.Journal of applied clinical medical physics · 2024Article
- Predicting treatment plan approval probability for high-dose-rate brachytherapy of cervical cancer using adversarial deep learning.Physics in medicine and biology · 2024Article
- Article
- Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer.Cureus · 2022Article
- IMRT and brachytherapy comparison in gynaecological cancer treatment: thinking over dosimetry and radiobiology.Ecancermedicalscience · 2019Article
- Vaginal stenosis and dilator use after pelvic brachytherapy.Revista CuidarteArticle
- Ensemble Learning for Three-dimensional Medical Image Segmentation of Organ at Risk in Brachytherapy Using Double U-Net, Bi-directional ConvLSTM U-Net, and Transformer Network.Journal of medical physicsArticle
- Diabetes Mellitus as a Prognostic Factor for Locally Advanced Rectal Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBrachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer.
methodsWe retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria.
resultsFifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD
conclusionsSevere adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of: less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.